Featured Research

from universities, journals, and other organizations

New agent may enhance effectiveness of radiotherapy

Date:
May 13, 2014
Source:
Manchester University
Summary:
The potential of a drug to improve the effectiveness of radiotherapy in stopping tumor growth has been demonstrated by scientists. There is increasing interest in using the body’s own immune system to attack tumor cells – a strategy that can be very effective without the side effects associated with conventional chemotherapy. Skin cancers, for instance, have been successfully treated using a topical cream, imiquimod, which recruits immune cells through a molecule known as toll-like receptor 7 (TLR7), a protein that recognizes foreign and potentially harmful material.

Scientists from The University of Manchester -- part of the Manchester Cancer Research Centre -- have demonstrated the potential of a drug to improve the effectiveness of radiotherapy in stopping tumor growth.

There is increasing interest in using the body's own immune system to attack tumor cells -- a strategy that can be very effective without the side effects associated with conventional chemotherapy.

Skin cancers have been successfully treated using a topical cream, imiquimod, which recruits immune cells through a molecule known as toll-like receptor 7 (TLR7), a protein that recognizes foreign and potentially harmful material.

Previously, researchers in Manchester have shown that they can also stimulate the immune system into generating an immune response against non-skin cancers by injecting an agent similar to TLR7 into the blood.

In collaboration with AstraZeneca and Dainippon Sumitomo Pharma, the Manchester group have looked at another molecule that activates TLR7, known as DSR-6434. Using mouse models of two different types of cancer, they investigated DSR-6434 on its own and in combination with radiotherapy and measured the effect on the primary tumor and the number of secondary tumors in the lungs.

Professor Ian Stratford, from Manchester Pharmacy School who, with Professor Tim Illidge, led the research published in the International Journal of Cancer, said: "We have already seen a strong immune system response from other immunotherapy agents in combination with radiation -- this new agent appears to be even more potent."

His team showed that administering DSR-6434 together with radiotherapy led to tumor shrinkage and increased long-term survival. They found that the combination treatment also reduced the occurrence of secondary lung tumors.

"It looks like there's good reason to use radiotherapy alongside immunotherapy agents in the treatment of solid tumors. These results strongly suggest that this sort of combination therapy should be evaluated in clinical trials with cancer patients," added Professor Stratford.


Story Source:

The above story is based on materials provided by Manchester University. Note: Materials may be edited for content and length.


Journal Reference:

  1. Amy L. Adlard, Simon J. Dovedi, Brian A. Telfer, Erina Koga-Yamakawa, Charlotte Pollard, Jamie Honeychurch, Timothy M. Illidge, Masashi Murata, David T. Robinson, Philip J. Jewsbury, Robert W. Wilkinson, Ian J. Stratford. A novel systemically administered toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models. International Journal of Cancer, 2014; DOI: 10.1002/ijc.28711

Cite This Page:

Manchester University. "New agent may enhance effectiveness of radiotherapy." ScienceDaily. ScienceDaily, 13 May 2014. <www.sciencedaily.com/releases/2014/05/140513092330.htm>.
Manchester University. (2014, May 13). New agent may enhance effectiveness of radiotherapy. ScienceDaily. Retrieved September 2, 2014 from www.sciencedaily.com/releases/2014/05/140513092330.htm
Manchester University. "New agent may enhance effectiveness of radiotherapy." ScienceDaily. www.sciencedaily.com/releases/2014/05/140513092330.htm (accessed September 2, 2014).

Share This




More Health & Medicine News

Tuesday, September 2, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

U.N. Says Ebola Travel Restrictions Will Cause Food Shortage

Newsy (Sep. 2, 2014) The U.N. says the problem is two-fold — quarantine zones and travel restrictions are limiting the movement of both people and food. Video provided by Newsy
Powered by NewsLook.com
Get on Your Bike! London Cycling Popularity Soars Despite Danger

Get on Your Bike! London Cycling Popularity Soars Despite Danger

AFP (Sep. 1, 2014) Wedged between buses, lorries and cars, cycling in London isn't for the faint hearted. Nevertheless the number of people choosing to bike in the British capital has doubled over the past 15 years. Duration: 02:27 Video provided by AFP
Powered by NewsLook.com
Can You Train Your Brain To Eat Healthy?

Can You Train Your Brain To Eat Healthy?

Newsy (Sep. 1, 2014) New research says if you condition yourself to eat healthy foods, eventually you'll crave them instead of junk food. Video provided by Newsy
Powered by NewsLook.com
We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins